arrow
M

Marcus O. Butler

University of Toronto
H指数:59
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Binimetinib和encorafenib用于非-V600E BRAF突变晚期实体瘤的治疗:来自BEAVER II期试验的结果

2026-01-030
OAAI
Nivolumab for Resected Stage III or IV Melanoma at 9 Years

纳武利尤单抗治疗已切除III期或IV期黑色素瘤9年结果

2025-10-015
PRE
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab

细胞外DNA中的T细胞受体库作为接受帕博利珠单抗治疗患者肿瘤浸润细胞的替代标志物

2025-08-270
PREAI
Elucidating divergent biology in uterine carcinosarcoma

阐明子宫癌肉瘤的异质性生物学

2025-08-230
PREAI
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

接受T细胞受体-CD3双特异性抗体tebentafusp治疗期间肿瘤免疫景观的演变

2025-04-010
OAAI
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

I期IMCnyeso研究,该研究是一种靶向NY-ESO-1表达性恶性病变的T细胞受体双特异性ImmTAC。

2025-04-010
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
2025-01-010
OAAI
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients

定制ctDNA用于高危黑色素瘤患者分子残留疾病的纵向检测

2024-11-011
OAAI
Characteristics of severe asthma patients requiring ICU treatment across the SHARP CRC
2024-10-300
PRE
Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study
2024-10-300
PRE
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
2024-10-080
OAAI
IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma

IDE196(darovasertib)联合crizotinib与研究者选择的治疗方案作为HLA-A2阴性转移性眼黑色素瘤的一线治疗

2024-09-010
PRE
Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers

血液T细胞适应性基因特征与ImmTAC双特异性T细胞衔接剂临床获益的关联

2024-09-010
PRE